Pharma BD Deal Intelligence
A collaboration that ended in acquisition: Roche's $110M-upfront, up-to-$6B allogeneic CAR-T pact with Poseida matured into Roche buying the company outright for $9.00/share plus a CVR, folding P-BCMA-ALLO1 fully in-house by January 2025.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Poseida Therapeutics on Thursday signed a strategic global collaboration with Roche to develop and commercialize allogeneic CAR-T cell therapies, in a deal…
Roche has agreed to pay Poseida Therapeutics up to $6 billion in upfront, equity, and milestone payments for global rights to develop and commercialize the…
Poseida 8-K (Jan 2025): completion of merger with Blue Giant Acquisition Corp., Roche subsidiary; shares converted to right to receive $9.00 plus CVR; Poseida…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
In August 2022, Poseida Therapeutics and Roche entered a strategic global collaboration on allogeneic (off-the-shelf) CAR-T therapies for hematologic malignancies including multiple myeloma and B-cell lymphomas. Roche paid $110M upfront (plus a ~$50M equity investment) and committed up to ~$6B in development, regulatory and commercial milestones, with tiered royalties. Lead programs were P-BCMA-ALLO1 (allogeneic BCMA CAR-T) and P-CD19CD20-ALLO1. The partnership matured and expanded through 2024, with Poseida receiving additional milestone payments. On November 26, 2024 Roche moved to acquire Poseida outright for $9.00/share (~$1.0B) plus a non-tradeable CVR of up to $4.00/share (total up to ~$1.5B); the acquisition closed January 8, 2025 via Blue Giant Acquisition Corp., delisting Poseida from Nasdaq and folding the collaboration and its allogeneic CAR-T platform fully into Roche.
35K US cases/yr · $24.0B Global multiple myeloma + B-cell NHL therapeutics market (2022) · ~$2.4B 2022 global CAR-T product sales (Yescarta, Kymriah, Breyanzi, Abecma, Carvykti, Tecartus)
Multiple myeloma is the second most common hematologic malignancy in the United States with approximately 35,000 new diagnoses and 12,000 deaths annually, while B-cell non-Hodgkin lymphomas (DLBCL, follicular lymphoma, mantle cell lymphoma, and CLL) collectively account for an additional ~80,000 new cases per year. The relapsed/refractory MM segment is the highest-priority CAR-T target because of its incurable nature, the existence of validated BCMA biology, and proof-of-clinical-concept from the autologous BCMA CAR-Ts ide-cel (Abecma) and cilta-cel (Carvykti) which delivered ORRs of 73-98% in heavily pretreated patients. The strategic prize is shifting CAR-T from autologous (4-6 week vein-to-vein, $400-475K wholesale, manufacturing-bottleneck-limited) to allogeneic off-the-shelf - the dominant unmet need that determines whether CAR-T scales to a $20B+ franchise or remains a centers-of-excellence-only therapy. Within B-cell lymphoma the dual CD19/CD20 allogeneic CAR-T approach is hypothesized to address antigen-loss escape mechanisms that drive relapse after CD19-only autologous products (Kymriah, Yescarta, Breyanzi).
The CAR-T competitive landscape splits into autologous (commercially dominant) and allogeneic (race for scale). Approved autologous CD19 CAR-Ts: Yescarta (axicabtagene ciloleucel, Gilead/Kite), Kymriah (tisagenlecleucel, Novartis), Breyanzi (lisocabtagene maraleucel, BMS), Tecartus (brexucabtagene autoleucel, Gilead/Kite). Approved autologous BCMA CAR-Ts: Abecma (idecabtagene vicleucel, BMS/2seventy bio) and Carvykti (ciltacabtagene autoleucel, J&J/Legend Biotech). Allogeneic CAR-T peers at deal time: Allogene Therapeutics (ALLO-501/501A CD19, ALLO-715 BCMA, all on FDA hold late 2021 then released 2022), CRISPR Therapeutics' CTX110/CTX112 (CD19) and CTX120 (BCMA), Caribou Biosciences' CB-010 (CD19) and CB-011 (BCMA), Precision BioSciences PBCAR0191 (CD19, discontinued 2022) and Cellectis UCART19. Adicet Bio's gamma-delta T-cell ADI-001 (CD20) competes in the dual-antigen B-cell space. Poseida's differentiation rests on the piggyBac transposon-based, non-viral, allogeneic, stem-cell-memory-enriched approach (P-BCMA-ALLO1 BCMA, P-CD19/20-ALLO1 dual-target) - the asset stack that drove Roche's $110M upfront and up to $6B biobucks commitment.
Roche entered a definitive merger agreement to acquire Poseida for $9.00/share (~$1.0B) plus a CVR of up to $4.00/share (total up to ~$1.5B), building on the 2022 allogeneic CAR-T collaboration.
Tender offer accepted (~66.11% tendered) and merger completed via Blue Giant Acquisition Corp.; Poseida delisted from Nasdaq and integrated into the Roche Group. The 2022 collaboration is absorbed into full ownership.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Poseida Therapeutics (this deal) | 2022 | $6.1B | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2022 deals · Roche Holding AG deals · Hematology deals